Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Kidney Int ; 90(1): 192-202, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-27178833

RESUMO

Hyporesponsiveness to erythropoiesis-stimulating agent therapy in dialysis patients is poorly understood. Some studies report an improvement in the erythropoiesis-stimulating agent resistance index (ERI) with hemodiafiltration (HDF) versus high-flux hemodialysis (HD). We explored ERI dynamics in 38,340 incident HDF and HD patients treated in 22 countries over a 7-year period. Groups were matched by propensity score at baseline (6 months after dialysis initiation). The follow-up period (mean of 1.31 years) was stratified into 1 month intervals with delta analyses performed for key ERI-related parameters. Dialysis modality, time interval, and polycystic kidney disease were included in a linear mixed model with the outcome ERI. Baseline ERI was nonsignificantly higher in HDF versus HD treatment. ERI decreased significantly faster in HDF-treated patients than in HD-treated patients, was decreased in both HD and HDF when patients were treated with intravenous darbepoetin alfa, but only in HDF when treated with intravenous recombinant human erythropoietin (rHuEPO). A clear difference between HD- and HDF-treated patients could only be found for patients with high baseline ERI and assigned to intravenous rHuEPO treatment. A significant advantage in terms of lower ERI for patients treated by HDF was found. Sensitivity analysis limited this advantage for HDF to those patients treated with intravenous rHuEPO (not darbepoetin alfa or subcutaneous rHuEPO) and to patients with a high baseline ERI. Thus, our results allow more accurate planning for future clinical trials addressing anemia management in dialysis patients.


Assuntos
Anemia/tratamento farmacológico , Resistência a Medicamentos , Hematínicos/farmacologia , Hemodiafiltração , Hemoglobinas/análise , Falência Renal Crônica/terapia , Diálise Renal , Administração Intravenosa , Idoso , Estudos de Coortes , Darbepoetina alfa/administração & dosagem , Darbepoetina alfa/farmacologia , Darbepoetina alfa/uso terapêutico , Eritropoetina/administração & dosagem , Eritropoetina/farmacologia , Eritropoetina/uso terapêutico , Feminino , Hematínicos/uso terapêutico , Humanos , Injeções Subcutâneas , Falência Renal Crônica/sangue , Masculino , Pessoa de Meia-Idade , Doenças Renais Policísticas/sangue , Doenças Renais Policísticas/terapia , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/uso terapêutico
2.
Nephrol Dial Transplant ; 28(9): 2383-92, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23787550

RESUMO

BACKGROUND: Different phosphate binders exert differing effects on bone mineral metabolism and levels of regulating hormones. The objective of this post hoc evaluation of the CALcium acetate MAGnesium carbonate (CALMAG) study was to compare the effects of calcium acetate/magnesium carbonate (CaMg) and a calcium-free phosphate binder, sevelamer-hydrochloride (HCl), on serum levels of fibroblast growth factor-23 (FGF-23) and markers of bone turnover. METHODS: This secondary analysis of the controlled, randomized CALMAG study, comparing the effect of CaMg and sevelamer-HCl on serum phosphorus (P), aimed to investigate the parameters described above. The analysis included 204 patients who completed the initial study per protocol (CaMg, n = 105; sevelamer-HCl, n = 99). RESULTS: The study showed that serum levels of FGF-23 were significantly reduced with CaMg and sevelamer-HCl, with no difference between groups at Week 25 [analysis of covariance (ANCOVA); log-intact FGF-23 (iFGF-23), P = 0.1573]. FGF-23 levels strongly correlated with serum P levels at all time points in both groups. The bone turnover parameters alkaline phosphatase (AP), bone AP (BAP), procollagen type 1 amino-terminal propeptide 1 (P1NP), osteoprotegerin (OPG), beta-crosslaps (ß-CTX) and tartrate-resistant acid phosphatase 5b (TRAP 5b) increased significantly in the sevelamer-HCl group; they remained almost unchanged in the CaMg group, after the initial phase of P lowering (ANCOVA, P < 0.0001 for all except OPG, P = 0.1718). CONCLUSIONS: CaMg and sevelamer-HCl comparably lower serum levels of iFGF-23. Changes in bone parameters were dependent on characteristics of the phosphate binder; in contrast with sevelamer-HCl, CaMg had no influence on bone turnover markers.


Assuntos
Acetatos/farmacologia , Osso e Ossos/metabolismo , Fatores de Crescimento de Fibroblastos/metabolismo , Hiperfosfatemia/tratamento farmacológico , Falência Renal Crônica/metabolismo , Magnésio/farmacologia , Poliaminas/farmacologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Fosfatase Alcalina/metabolismo , Biomarcadores/metabolismo , Compostos de Cálcio/farmacologia , Quelantes/farmacologia , Ensaio de Imunoadsorção Enzimática , Feminino , Fator de Crescimento de Fibroblastos 23 , Seguimentos , Taxa de Filtração Glomerular , Humanos , Hiperfosfatemia/metabolismo , Falência Renal Crônica/tratamento farmacológico , Testes de Função Renal , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/metabolismo , Prognóstico , Diálise Renal , Fatores de Risco , Sevelamer , Adulto Jovem
3.
Przegl Lek ; 62(6): 514-6, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16225109

RESUMO

The aim of this paper is to present a case of 46-yr-old man, poisoned with methanol, treated with ethanol and haemodialysis. According to history, he was alcoholic, but without any others complaints, except mild hypertension. During the clinical course of methanol poisoning ECG revealed pathological Q wave and ST segment elevation in leads II, III, aVF, without increased cardiac enzymes activity. As a sequel of acute methanol poisoning irreversible bitemporal loss of vision was confirmed four months after poisoning. Cardiologic examination at the same time confirmed past acute coronary episode.


Assuntos
Hemianopsia/induzido quimicamente , Metanol/intoxicação , Solventes/intoxicação , Doença das Coronárias/induzido quimicamente , Eletrocardiografia , Hemianopsia/terapia , Humanos , Masculino , Pessoa de Meia-Idade , Intoxicação/complicações , Transtornos Relacionados ao Uso de Substâncias/complicações , Fatores de Tempo , Baixa Visão/induzido quimicamente , Acuidade Visual
4.
Pol Arch Med Wewn ; 112 Spec No: 139-46, 2004 Oct.
Artigo em Polonês | MEDLINE | ID: mdl-15669210

RESUMO

Hypertension occurs in above half of elderly patients with the most common type of hypertension being Isolated Systolic Hypertension (ISH). Because of very well documented benefits of ISH therapy in elderly patients attention must be paid to the successful therapy which means: appropriate arterial blood pressure measurement and correct diagnosis of ISH as well as individualization of therapy protocols in accordance with principle: "start low, go slow".


Assuntos
Envelhecimento , Anti-Hipertensivos/uso terapêutico , Hipertensão/diagnóstico , Hipertensão/terapia , Fatores Etários , Idoso , Envelhecimento/patologia , Pressão Sanguínea/efeitos dos fármacos , Exercício Físico , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/fisiopatologia , Estilo de Vida , Educação de Pacientes como Assunto/métodos , Prevenção Primária/métodos , Abandono do Hábito de Fumar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...